Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 10/2022

25.07.2022 | Breast Oncology

Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients

verfasst von: Gabriel De la Cruz Ku, MD, Manish Karamchandani, MD, Diego Chambergo-Michilot, BS, Alexis R. Narvaez-Rojas, MD, Michael Jonczyk, MD, Fortunato S. Príncipe-Meneses, BS, David Posawatz, MS, Salvatore Nardello, DO, MBS, Abhishek Chatterjee, MD, MBA

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

There have been conflicting studies reporting on survival advantages between breast-conserving surgery with radiotherapy (BCS) in comparison with mastectomy. Our aim was to compare the efficacy of BCS and mastectomy in terms of overall survival (OS) comparing all past published studies.

Methods

We performed a comprehensive review of literature through October 2021 in PubMed, Scopus, and EMBASE. The studies included were randomized controlled trials (RCTs) and cohorts that compare BCS versus mastectomy. We excluded studies that included male sex, stage 0, distant metastasis at diagnosis, bilateral synchronous cancer, neoadjuvant radiation/chemotherapy, and articles with incomplete data. We performed a meta-analysis following the random-effect model with the inverse variance method.

Results

From 18,997 publications, a total of 30 studies were included in the final analysis: 6 studies were randomized trials, and 24 were retrospective cohorts. A total of 1,802,128 patients with a follow-up ranging from 4 to 20 years were included, and 1,075,563 and 744,565 underwent BCS and mastectomy, respectively. Among the population, BCS is associated with improved OS compared with mastectomy [relative risk (RR) 0.64, 95% confidence interval (CI) 0.55–0.74]. This effect was similar when analysis was performed in cohorts and multi-institutional databases (RR 0.57, 95% CI 0.49–0.67). Furthermore, the benefit of BCS was stronger in patients who had less than 10 years of follow-up (RR 0.54, 95% CI 0.46–0.64).

Conclusions

Patients who underwent BCS had better OS compared with mastectomy. Such results depicting survival advantage, especially using such a large sample of patients, may need to be included in the shared surgical decision making when discussing breast cancer treatment with patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: a systematic review. Clin Breast Cancer. 2018;18(4):e539–54.PubMedCrossRef
2.
Arndt V, Stegmaier C, Ziegler H, Brenner H. Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol. 2008;134(12):1311–8.PubMedCrossRef
3.
van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158–70.PubMedCrossRef
4.
Landercasper J, Ramirez LD, Borgert AJ, Ahmad HF, Parsons BM, Dietrich LL, et al. A reappraisal of the comparative effectiveness of lumpectomy versus mastectomy on breast cancer survival: a propensity score-matched update from the national cancer data base (NCDB). Clin Breast Cancer. 2019;19(3):e481–93.PubMedCrossRef
5.
Li H, Chen Y, Wang X, Tang L, Guan X. T1–2N0M0 Triple-negative breast cancer treated with breast-conserving therapy has better survival compared to mastectomy: a SEER population-based retrospective analysis. Clin Breast Cancer. 2019;19(6):e669–82.PubMedCrossRef
6.
Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF. Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol. 2015;22(12):3836–45.PubMedPubMedCentralCrossRef
7.
de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg. 2021;156(7):628–37.PubMedPubMedCentralCrossRef
8.
Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, et al. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers. 2019;11(2):160.PubMedCentralCrossRef
9.
Ratosa I, Plavc G. Improved survival after breast-conserving therapy compared with mastectomy in stage I-IIa breast cancer. 2021;13(16):4044
10.
Yoo GS, Park W, Yu JI, Choi DH, Kim YJ, Shin KH, et al. Comparison of breast conserving surgery followed by radiation therapy with mastectomy alone for pathologic n1 breast cancer patients in the era of anthracycline plus taxane-based chemotherapy: a multicenter retrospective study (krog 1418). Cancer Research Treat. 2019;51(3):1041–51.CrossRef
11.
Lagendijk M, van Maaren MC. Breast conserving therapy and mastectomy revisited Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. 2018;142(1):165–75.
12.
Kim H, Lee SB. Survival of breast-conserving surgery plus radiotherapy versus total mastectomy in early breast cancer. Annals of surgical oncology. 2021;28(9):5039–47.PubMedCrossRef
13.
Almahariq MF, Quinn TJ, Siddiqui Z, Jawad MS, Chen PY, Gustafson GS, et al. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. Radiother Oncol. 2020;142:186–94.PubMedCrossRef
14.
Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41(10):1417–22.PubMedCrossRef
15.
Onitilo AA, Engel JM, Stankowski RV, Doi SAR. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res. 2015;13(2):65–73.PubMedPubMedCentralCrossRef
16.
Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1387–93.PubMedCrossRef
17.
Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13(4):412–9.PubMedCrossRef
18.
Blichert-Toft M, Brincker H, Andersen JA, Andersen KW, Axelsson CK, Mouridsen HT, et al. A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. Acta Oncol. 1988;27(6a):671–7.PubMedCrossRef
19.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med. 2002;347(16):1227–32.PubMedCrossRef
20.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med. 2002;347(16):1233–41.PubMedCrossRef
21.
Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, et al. Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat. 2012;132(1):197–203.PubMedCrossRef
22.
van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143–50.PubMedCrossRef
23.
Lee HD, Yoon DS, Koo JY, Suh CO, Jung WH, Oh KK. Breast conserving therapy in stage I & II breast cancer in Korea. Breast Cancer Res Treat. 1997;44(3):193–9.PubMedCrossRef
24.
Fentiman IS, van Zijl J, Karydas I, Chaudary MA, Margreiter R, Legrand C, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen. Eur J Cancer. 2003;39(3):300–8.PubMedCrossRef
25.
Gori J, Castaño R, Engel H, Toziano M, Fischer C, Maletti G. Conservative treatment vs. mastectomy without radiotherapy in aged women with breast cancer—a prospective and randomized trial. Zentralbl Gynaekol. 2000;122(6):311–7.
26.
Haque W, Verma V, Hatch S, Klimberg VS, Butler EB, Teh BS. Omission of chemotherapy for low-grade, luminal A N1 breast cancer: patterns of care and clinical outcomes. Breast. 2018;41:67–73.PubMedCrossRef
27.
Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119(7):1402–11.PubMedCrossRef
28.
Lazow SP, Riba L, Alapati A. Comparison of breast-conserving therapy vs mastectomy in women under age 40: national trends and potential survival implications. Breast J. 2019;25(4):578–84.PubMedCrossRef
29.
Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun. 2019;39(1):60.CrossRef
30.
Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, et al. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2011;125(3):803–13.PubMedCrossRef
31.
Mogal HD, Clark C, Dodson R, Fino NF, Howard-McNatt M. Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol. 2017;24(1):100–7.PubMedCrossRef
32.
Wu SG, Zhang WW, Sun JY, Li FY, Chen YX, He ZY. Postoperative radiotherapy for invasive micropapillary carcinoma of the breast: an analysis of surveillance, epidemiology, and end results database. Cancer Manag Res. 2017;9:453–9.PubMedPubMedCentralCrossRef
33.
Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18(1):94–103.PubMedCrossRef
34.
Xia L-Y, Xu W-Y, Hu Q-L. The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: a population-based study. PLoS One. 2021;16(9):e0256893.PubMedPubMedCentralCrossRef
35.
Yu P, Tang H, Zou Y, Liu P, Tian W, Zhang K, et al. Breast-conserving therapy versus mastectomy in young breast cancer patients concerning molecular subtypes: a SEER population-based study. Cancer Control. 2020;27(1):1073274820976667.PubMedPubMedCentralCrossRef
36.
Yu TJ, Liu YY, Hu X, Di GH. Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma. Eur J Surg Oncol. 2018;44(11):1703–7.PubMedCrossRef
37.
Zhang J, Yang C, Lei C, Zhang Y, Ji F, Gao H, et al. Survival outcomes after breast-conserving therapy compared with mastectomy for patients with early-stage metaplastic breast cancer: a population-based study of 2412 patients. Breast. 2021;58:10–7.PubMedPubMedCentralCrossRef
38.
IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247.PubMedPubMedCentralCrossRef
39.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRef
40.
Higgins JPT, (ed.), Thomas J, (ed.), Chandler J, (ed.), Cumpston M, (ed.), Li T, (ed.), Page M, (ed.) et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester UK: Wiley-Blackwell, 2019. pp. 703
41.
Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. Med Res Methodol. 2014;14(1):45.
42.
Bhoo-Pathy N, Verkooijen HM, Wong FY, Pignol JP, Kwong A, Tan EY, et al. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: a historical cohort study. Int J Cancer. 2015;137(10):2504–12.PubMedCrossRef
43.
Chen K, Liu J, Zhu L, Su F, Song E, Jacobs LK. Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: a NCDB analysis. Oncotarget. 2015;6(37):40127–40.PubMedPubMedCentralCrossRef
44.
de Boniface J, Frisell J, Bergkvist L, Andersson Y. Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation. Br J Surg. 2018;105(12):1607–14.PubMedPubMedCentralCrossRef
45.
De-la-Cruz-Ku G, Valcarcel B, Morante Z, Möller MG, Lizandro S, Rebaza LP, et al. Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: a propensity score analysis. Breast Dis. 2020;39(1):29–35.
46.
Kurian AW, Lichtensztajn DY, Keegan THM, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in california, 1998–2011. JAMA. 2014;312(9):902–14.PubMedPubMedCentralCrossRef
47.
Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, et al. Preoperative breast MRI and mortality in older women with breast cancer. Breast Cancer Res Treat. 2018;170(1):149–57.PubMedPubMedCentralCrossRef
48.
van den Broek AJ, Schmidt MK, van’t Veer LJ, Oldenburg HS, Rutgers EJ, Russell NS, Smit VT, Voogd AC, Koppert LB, Siesling S, Jobsen JJ. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg. 2019;270(2):364–72.
49.
Vinh-Hung V, Burzykowski T, Van de Steene J, Storme G, Soete G. Post-surgery radiation in early breast cancer: survival analysis of registry data. Radiother Oncol. 2002;64(3):281–90.PubMedCrossRef
50.
Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008;206(1):66–75.PubMedCrossRef
51.
Sarrazin D, Lê MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989;14(3):177–84.PubMedCrossRef
52.
Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;11:19–25.
53.
Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672–81.PubMedCrossRef
54.
55.
Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJD, Tamaskovics B, et al. Recent advances in radiotherapy of breast cancer. Radiat Oncol J. 2020;15(1):71.CrossRef
56.
Shah C, Al-Hilli Z, Vicini F. Advances in breast cancer radiotherapy: implications for current and future practice. J Oncol Pract. 2021;17(12):697–706.CrossRef
57.
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.PubMedPubMedCentralCrossRef
58.
59.
60.
Golshan M, Loibl S, Wong SM, Huober JB, O’Shaughnessy J, Rugo HS, et al. Breast Conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410.PubMedPubMedCentralCrossRef
61.
Arlow RL, Paddock LE, Niu X, Kirstein L, Haffty BG, Goyal S, et al. Breast-conservation therapy after neoadjuvant chemotherapy does not compromise 10-year breast cancer-specific mortality. Am J Clin Oncol. 2018;41(12):1246–51.PubMedPubMedCentralCrossRef
62.
Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res. 2009;11(4):R44.PubMedPubMedCentralCrossRef
63.
Mannu GS, Wang Z, Broggio J, Charman J, Cheung S, Kearins O, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988–2014: population based observational cohort study. BMJ. 2020;369:m1570.PubMedPubMedCentralCrossRef
64.
Shah TA, Guraya SS. Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct. 2017;5(2):59–69.PubMedCrossRef
65.
66.
Radhakrishna S, Agarwal S, Parikh PM, Kaur K, Panwar S, Sharma S, et al. Role of magnetic resonance imaging in breast cancer management. South Asian J Cancer. 2018;7(2):69–71.PubMedPubMedCentralCrossRef
67.
Kleinknecht JH, Ciurea AI, Ciortea CA. Pros and cons for breast cancer screening with tomosynthesis—a review of the literature. Med Pharm Rep. 2020;93(4):335–41.PubMedPubMedCentral
68.
Wilczek B, Wilczek HE, Rasouliyan L, Leifland K. Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: report from a hospital-based, high-volume, single-center breast cancer screening program. Eur J Radiol. 2016;85(9):1554–63.PubMedCrossRef
69.
Harada-Shoji N, Suzuki A, Ishida T, Zheng Y-F, Narikawa-Shiono Y, Sato-Tadano A, et al. Evaluation of adjunctive ultrasonography for breast cancer detection among women aged 40–49 years with varying breast density undergoing screening mammography: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4(8):e2121505.PubMedPubMedCentralCrossRef
70.
Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168(1):98–104.PubMedCrossRef
71.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.PubMedPubMedCentralCrossRef
72.
Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5(3):465–77.PubMedPubMedCentralCrossRef
73.
Horton S, Camacho Rodriguez R, Anderson BO, Aung S, Awuah B, Delgado Pebé L, et al. Health system strengthening: Integration of breast cancer care for improved outcomes. Cancer. 2020;126(S10):2353–64.PubMedCrossRef
74.
Yabroff KR, Gansler T, Wender RC, Cullen KJ, Brawley OW. Minimizing the burden of cancer in the United States: goals for a high-performing health care system. Cancer J Clin. 2019;69(3):166–83.CrossRef
75.
Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, et al. NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. J Oncol. 1996;10:47–75.
76.
Arrojo EE, Martinez A, Vicini FA. Trends in breast cancer treatment in United States from 2000 to 2011: Consequences of 2004 National Comprehensive Cancer Network (NCCN) guidelines change. J Clin Oncol. 2014;32(26_suppl):69–69.CrossRef
77.
Falck A-K, Fernö M, Bendahl P-O, Rydén L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer. 2013;13(1):558.PubMedPubMedCentralCrossRef
78.
Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–505.PubMedPubMedCentralCrossRef
79.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.PubMedPubMedCentralCrossRef
80.
Oh D-Y, Bang Y-J. HER2-targeted therapies—a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.PubMedCrossRef
81.
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233–50.PubMedCrossRef
82.
Copeland RL, Kanaan Y. New targets in triple-negative breast cancer. Nat Rev Clin Oncol. 2021;21(12):744–744.
83.
Char S, Bloom JA, Erlichman Z, Jonczyk MM, Chatterjee A. A comprehensive literature review of patient reported outcome measures (PROMs) among common breast reconstruction options: what types of breast reconstruction score well? Breast J. 2021;27:322–9.PubMedCrossRef
Metadaten
Titel
Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
verfasst von
Gabriel De la Cruz Ku, MD
Manish Karamchandani, MD
Diego Chambergo-Michilot, BS
Alexis R. Narvaez-Rojas, MD
Michael Jonczyk, MD
Fortunato S. Príncipe-Meneses, BS
David Posawatz, MS
Salvatore Nardello, DO, MBS
Abhishek Chatterjee, MD, MBA
Publikationsdatum
25.07.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12133-8

Weitere Artikel der Ausgabe 10/2022

Annals of Surgical Oncology 10/2022 Zur Ausgabe

Breast Oncology

The Influence of Body Mass Index on the Histopathology and Outcomes of Patients Diagnosed with Atypical Breast Lesions

Breast Oncology

Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study

ASO Author Reflections

ASO Author Reflections: Breast-Specific Sensuality in the Sexually Inactive Breast Cancer Survivor

Breast Oncology

Impact of Locoregional Treatment on Survival in Young Patients with Early-Stage Breast Cancer undergoing Upfront Surgery

ASO Visual Abstract

ASO Visual Abstract: Analysis of Breast Cancer Patients’ Understanding and Worry About Lymphedema

ASO Visual Abstract

ASO Visual Abstract: Breast-Specific Sensuality in Breast Cancer Survivors – Sexually Active or Not

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise